Form 4: CORT Officer Sells Shares After Option Exercise

Corcept Therapeutics Chief Development Officer William Guyer sold 14 shares of common stock after exercising options, as per a pre-arranged 10b5-1 plan.

Summary

• William Guyer, Chief Development Officer of Corcept Therapeutics Inc. (CORT), reported changes in beneficial ownership.
• On August 5, 2025, Guyer acquired 14 shares of common stock by exercising stock options at a price of $21.65 per share.
• Concurrently, on August 5, 2025, Guyer disposed of 14 shares of common stock at a price of $71.77 per share.
• The sale was conducted under a Rule 10b5-1 trading plan adopted on November 27, 2024.
• Following these transactions, Guyer directly owns 5,487 shares of common stock and 385,007 stock options.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction where an executive exercised options and sold a very small number of shares at a profit. The transaction was pre-planned under a 10b5-1 plan, which reduces the negative perception of an insider sale. The minimal volume of shares makes the overall impact neutral to slightly positive, as it shows the executive realizing value from their compensation.

Positives

• The insider exercised options at a lower price ($21.65) and sold shares at a significantly higher price ($71.77), indicating a profitable transaction for the insider.
• The transaction was conducted under a pre-arranged 10b5-1 plan, which suggests a planned, non-discretionary sale.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market, though the extremely small number of shares (14) makes this negligible.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, as it is a report of past insider transactions.

Industry Context

This Form 4 details a routine insider transaction, common for executives managing their equity compensation. It does not provide information that would indicate broader industry trends or competitive shifts.

Related Party Transactions

• The reported transaction itself is a related party transaction, involving the Chief Development Officer's exercise of stock options and sale of company shares.

Stakeholder Impact

• Shareholders: Minimal direct impact due to the extremely small number of shares involved (14 shares). The sale by an insider could be seen as a slight negative, but the pre-arranged 10b5-1 plan mitigates this perception.
• Employees: No direct impact.

Key Dates

Recommendation

This Form 4 details a routine, pre-planned insider transaction involving a very small number of shares (14). While the insider profited from exercising options and selling shares, the volume is negligible and does not provide new material information to alter an investment thesis for Corcept Therapeutics. The transaction is consistent with typical executive compensation management and does not signal any significant change in company fundamentals or outlook.

Keywords

Corcept Therapeutics, CORT, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, William Guyer, Chief Development Officer, Equity Sales